{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:50:38Z","timestamp":1784055038351,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5F31CA236051"],"award-info":[{"award-number":["5F31CA236051"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5P50CA098252"],"award-info":[{"award-number":["5P50CA098252"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.celrep.2021.109838","type":"journal-article","created":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T01:47:21Z","timestamp":1633484841000},"page":"109838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["In\u00a0vivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential"],"prefix":"10.1016","volume":"37","author":[{"given":"Brandon","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jui","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ssu-Hsueh","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya Chea","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangmei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Egbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia J.","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8181-9517","authenticated-orcid":false,"given":"Evan M.","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron A.R.","family":"Tobian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Milstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.S.","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzyy-Choou","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9170-7797","authenticated-orcid":false,"given":"Chien-Fu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2021.109838_bib1","doi-asserted-by":"crossref","first-page":"15917","DOI":"10.1038\/s41598-020-72528-z","article-title":"Structural and functional modelling of SARS-CoV-2 entry in animal models","volume":"10","author":"Brooke","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2021.109838_bib2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1128\/JVI.78.2.751-757.2004","article-title":"Efficient intracellular assembly of papillomaviral vectors","volume":"78","author":"Buck","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2021.109838_bib48","series-title":"Science Brief: COVID-19 Vaccines and Vaccination","year":"2021"},{"key":"10.1016\/j.celrep.2021.109838_bib49","unstructured":"CDC (2021b). https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/science\/science-briefs\/scientific-brief-emerging-variants.html."},{"key":"10.1016\/j.celrep.2021.109838_bib5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41586-021-03471-w","article-title":"Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma","volume":"593","author":"Cele","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2021.109838_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-021-03412-7","article-title":"Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies","volume":"593","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2021.109838_bib7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41418-020-00720-9","article-title":"COVID-19 vaccines: where we stand and challenges ahead","volume":"28","author":"Forni","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.celrep.2021.109838_bib8","article-title":"The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: A Free energy of perturbation study","author":"Fratev","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.celrep.2021.109838_bib9","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","volume":"591","author":"Gaebler","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2021.109838_bib10","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1128\/JVI.78.17.9007-9015.2004","article-title":"Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein","volume":"78","author":"Giroglou","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2021.109838_bib11","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1126\/science.abc4730","article-title":"Adaptation of SARS-CoV-2 in BALB\/c mice for testing vaccine efficacy","volume":"369","author":"Gu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.celrep.2021.109838_bib12","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(21)00575-4","article-title":"Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study","volume":"397","author":"Hansen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.celrep.2021.109838_bib13","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.it.2020.10.004","article-title":"Mechanisms of SARS-CoV-2 Transmission and Pathogenesis","volume":"41","author":"Harrison","year":"2020","journal-title":"Trends Immunol."},{"key":"10.1016\/j.celrep.2021.109838_bib14","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.cell.2020.06.011","article-title":"A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies","volume":"182","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2021.109838_bib15","article-title":"Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers","author":"Heaney","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.celrep.2021.109838_bib16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.gendis.2020.07.006","article-title":"Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2","volume":"7","author":"Hu","year":"2020","journal-title":"Genes Dis."},{"key":"10.1016\/j.celrep.2021.109838_bib17","article-title":"The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera","author":"Jangra","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.celrep.2021.109838_bib18","doi-asserted-by":"crossref","first-page":"578825","DOI":"10.3389\/fcell.2021.578825","article-title":"The Mechanisms and Animal Models of SARS-CoV-2 Infection","volume":"9","author":"Jia","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.celrep.2021.109838_bib19","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMe2035678","article-title":"(A Little) Clarity on Convalescent Plasma for Covid-19","volume":"384","author":"Katz","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2021.109838_bib20","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1172\/JCI142004","article-title":"Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population","volume":"130","author":"Klein","year":"2020","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.celrep.2021.109838_bib21","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2021.109838_bib22","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","article-title":"The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2021.109838_bib23","doi-asserted-by":"crossref","first-page":"n296","DOI":"10.1136\/bmj.n296","article-title":"Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant","volume":"372","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.celrep.2021.109838_bib24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/JVI.02012-06","article-title":"Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus","volume":"81","author":"McCray","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2021.109838_bib25","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.abg6105","article-title":"Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera","volume":"371","author":"Muik","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.celrep.2021.109838_bib26","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","article-title":"Animal models for COVID-19","volume":"586","author":"Mu\u00f1oz-Fontela","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2021.109838_bib27","doi-asserted-by":"crossref","first-page":"e02257-20","DOI":"10.1128\/JCM.02257-20","article-title":"Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers","volume":"59","author":"Patel","year":"2021","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.celrep.2021.109838_bib28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41586-020-2895-3","article-title":"Spike mutation D614G alters SARS-CoV-2 fitness","volume":"592","author":"Plante","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2021.109838_bib29","article-title":"Eicosanoid signaling as a therapeutic target in middle-aged mice with severe COVID-19","author":"Roy Wong","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.celrep.2021.109838_bib30","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(21)00183-5","article-title":"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence","volume":"397","author":"Sabino","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.celrep.2021.109838_bib31","article-title":"The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation","author":"Santos","year":"2021","journal-title":"bioRvix"},{"key":"10.1016\/j.celrep.2021.109838_bib32","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2021.109838_bib33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2021.109838_bib34","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s12250-020-00252-z","article-title":"A Comprehensive Review of Animal Models for Coronaviruses: SARS-CoV-2, SARS-CoV, and MERS-CoV","volume":"35","author":"Singh","year":"2020","journal-title":"Virol. Sin."},{"key":"10.1016\/j.celrep.2021.109838_bib35","doi-asserted-by":"crossref","first-page":"eabd2223","DOI":"10.1126\/scitranslmed.abd2223","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.celrep.2021.109838_bib36","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","article-title":"Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment","volume":"182","author":"Sun","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2021.109838_bib37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2021.109838_bib38","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2021.109838_bib39","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","author":"Wang","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.celrep.2021.109838_bib40","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","article-title":"Generation of VSV pseudotypes using recombinant \u0394G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines","volume":"169","author":"Whitt","year":"2010","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.celrep.2021.109838_bib41","series-title":"Covid-19 Response FundDonateWHO Coronavirus (COVID-19) Dashboard","year":"2021"},{"key":"10.1016\/j.celrep.2021.109838_bib42","series-title":"COVID-19 vaccine tracker and landscape","year":"2021"},{"key":"10.1016\/j.celrep.2021.109838_bib43","series-title":"Tracking SARS-CoV-2 variants","year":"2021"},{"key":"10.1016\/j.celrep.2021.109838_bib44","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.celrep.2021.109838_bib45","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cell.2020.09.032","article-title":"SARS-CoV-2 Spike protein variant D614G increases infectivity and retains sensitivity to antibodies that target the receptor binding domain","volume":"183","author":"Yurkovetskiy","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2021.109838_bib46","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jama.2021.1612","article-title":"Emergence of a Novel SARS-CoV-2 Variant in Southern California","volume":"325","author":"Zhang","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.celrep.2021.109838_bib47","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124721013024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124721013024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T11:30:35Z","timestamp":1761910235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124721013024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2211124721013024"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2021.109838","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u00a0vivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2021.109838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"109838"}}